Literature DB >> 23141052

Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).

Kohei Ogawa1, Hironori Morito, Ayako Hasegawa, Natsuko Daikoku, Fumi Miyagawa, Aiko Okazaki, Takaya Fukumoto, Nobuhiko Kobayashi, Takahiko Kasai, Hideaki Watanabe, Hirohiko Sueki, Masafumi Iijima, Mikiko Tohyama, Koji Hashimoto, Hideo Asada.   

Abstract

BACKGROUND: Drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS) is a serious acute drug reaction with fever, cutaneous eruption, lymphadenopathy, and several visceral dysfunctions. Eosinophilia is a common hematological abnormality in DIHS/DRESS suggesting that the Th2-type immune response is involved. Thymus and activation-regulated chemokine (TARC/CCL17) is a family of CC chemokines known to play an important role in Th2-mediated immune-inflammatory processes.
OBJECTIVE: We investigated the pathogenic role of TARC in patients with DIHS.
METHODS: Sera were obtained from 8 patients with DIHS, 7 patients with Stevens-Johnson syndrome/Toxic epidermal necrolysis (SJS/TEN), and 14 patients with drug-induced maculopapular exanthema (MPE). Serum TARC levels were measured by ELISA. TARC levels were then compared with clinical symptoms and various hematological parameters. In addition, a biopsy was taken from the lesional skin of patients with DIHS and stained with anti-TARC Ab and anti-CD11c Ab.
RESULTS: Serum TARC levels in patients with DIHS were significantly higher than those in patients with SJS/TEN and MPE during the acute phase. Serum TARC levels in DIHS patients correlated with skin eruptions, serum sIL-2R levels, eosinophil counts, and serum IL-5 levels. Immunohistochemical staining revealed that TARC was mainly expressed on CD11c+ dermal dendritic cells in patients with DIHS.
CONCLUSION: Serum TARC levels may be associated with the initial presentation of DIHS as well as disease activity during the course. Thus, they could be useful as an indicator for early diagnosis and assessment of disease activity in DIHS. CD11c+ dendritic cells may be the main source of TARC in patients with DIHS.
Copyright © 2012 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23141052     DOI: 10.1016/j.jdermsci.2012.10.002

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  24 in total

Review 1.  [Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a review].

Authors:  S Ständer; D Metze; T Luger; T Schwarz
Journal:  Hautarzt       Date:  2013-08       Impact factor: 0.751

Review 2.  Hair disorders in patients with cancer.

Authors:  Azael Freites-Martinez; Jerry Shapiro; Shari Goldfarb; Julie Nangia; Joaquin J Jimenez; Ralf Paus; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2018-04-14       Impact factor: 11.527

Review 3.  Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS.

Authors:  Hannah Stirton; Neil H Shear; Roni P Dodiuk-Gad
Journal:  Biomedicines       Date:  2022-04-26

4.  Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

Authors:  Natsumi Hama; Riichiro Abe; Andrew Gibson; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-15

Review 5.  The Conundrum of Lung Disease and Drug Hypersensitivity-like Reactions in Systemic Juvenile Idiopathic Arthritis.

Authors:  Bryce A Binstadt; Peter A Nigrovic
Journal:  Arthritis Rheumatol       Date:  2022-05-29       Impact factor: 15.483

Review 6.  What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?

Authors:  Julien Catherine; Florence Roufosse
Journal:  Semin Immunopathol       Date:  2021-05-19       Impact factor: 9.623

Review 7.  Eosinophilic Drug Allergy.

Authors:  Merin Kuruvilla; David A Khan
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 10.817

Review 8.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.

Authors:  Marwan H Adwan
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.686

Review 9.  Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.

Authors:  Teresa Bellón
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.228

10.  Correlation Between Expression of CD134, a Human Herpesvirus 6 Cellular Receptor, on CD4+ T cells and Th2-type Immune Responses in Drug-induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.

Authors:  Fumi Miyagawa; Yuki Nakamura-Nishimura; Yushi Kanatani; Hideo Asada
Journal:  Acta Derm Venereol       Date:  2020-03-31       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.